Evidence map›Paper›PMID 29487402›Full record

ArticleMolecular psychiatry2019

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Allison C Nugent, Elizabeth D Ballard, Todd D Gould, Lawrence T Park, Ruin Moaddel, Nancy E Brutsche, Carlos A Zarate

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 145 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00088699 phase1 / phase2completednot on this map

Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist

TypeinterventionalSponsorNational Institute of Mental Health (NIMH)Ran2004 to 2017Enrolled67ConditionsDepression, Mood Disorders, Major DepresssionArmsKetamine, Placebo
NCT04877977 recruitingnot on this mapstarted 2021, after this paper: background citation

Long-term Observation of Participants With Mood Disorders

TypeobservationalSponsorNational Institute of Mental Health (NIMH)Ran2021 to 2028Enrolled1,000ConditionsDepression, Suicide Risk
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. REM density predicts rapid antidepressant response to ketamine in individuals with treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  10. Trial
  11. Entactogen Effects of Ketamine: A Reverse-Translational Study.The American journal of psychiatry · 2024
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  18. Trial
  19. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  20. Trial

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Allison C NugentExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. nugenta@mail.nih.gov.
Elizabeth D BallardExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Todd D GouldDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Lawrence T ParkExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6570-686X
Ruin MoaddelLaboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Nancy E BrutscheExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Therapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2M
Glutamatergic Modulators--Rapid Sustained AntidepressantZ01MH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MANJI, HUSSEINI K · 2005 to 2008
$621k
BLRD VA I01 BX004062Intramural NIH HHS Z01 MH002857Intramural NIH HHS Z99 MH999999Intramural NIH HHS ZIA MH002857NIMH NIH HHS R01 MH107615
6 · The paper itself

Abstract

Ketamine's mechanism of action was assessed using gamma power from magnetoencephalography (MEG) as a proxy measure for homeostatic balance in 35 unmedicated subjects with major depressive disorder (MDD) and 25 healthy controls enrolled in a double-blind, placebo-controlled, randomized cross-over trial of 0.5 mg/kg ketamine. MDD subjects showed significant improvements in depressive symptoms, and healthy control subjects exhibited modest but significant increases in depressive symptoms for up to 1 day after ketamine administration. Both groups showed increased resting gamma power following ketamine. In MDD subjects, gamma power was not associated with the magnitude of the antidepressant effect. However, baseline gamma power was found to moderate the relationship between post-ketamine gamma power and antidepressant response; specifically, higher post-ketamine gamma power was associated with better response in MDD subjects with lower baseline gamma, with an inverted relationship in MDD subjects with higher baseline gamma. This relationship was observed in multiple regions involved in networks hypothesized to be involved in the pathophysiology of MDD. This finding suggests biological subtypes based on the direction of homeostatic dysregulation and has important implications for inferring ketamine's mechanism of action from studies of healthy controls alone.

Indexed as

AdultAntidepressive AgentsCase-Control StudiesCross-Over StudiesDepressionDepressive Disorder, Treatment-ResistantDouble-Blind MethodElectrophysiological PhenomenaFemaleHumansKetamineMagnetoencephalographyMajor Depressive DisorderMaleMiddle AgedAntidepressive AgentsKetamine

Identifiers

PMID29487402
PMCPMC6111001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.